A Randomised Single-Blind Study to Improve Health-related Quality of Life as Measured by the Short-Form 36 (SF-36) Vitality Score by Correcting Anemia With Aranesp (Darbepoetin Alfa) in the Elderly.
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2014
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms STIMULATE
- Sponsors Amgen
- 20 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Jan 2010 Actual patient number (51) added as reported by ClinicalTrials.gov.
- 14 May 2008 The expected completion date for this trial has changed from September 2008 to May 2009 according to ClinicalTrials.gov